CN111920757A - Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt - Google Patents
Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt Download PDFInfo
- Publication number
- CN111920757A CN111920757A CN202011006481.9A CN202011006481A CN111920757A CN 111920757 A CN111920757 A CN 111920757A CN 202011006481 A CN202011006481 A CN 202011006481A CN 111920757 A CN111920757 A CN 111920757A
- Authority
- CN
- China
- Prior art keywords
- bioactive
- salicylic acid
- salt
- hesperetin
- purification solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a cleaning solution for treating acarid dermatitis based on synergy of bioactive colloidal sulfur particles and methionine salt, which comprises the following components by weight: 1-15% of bioactive colloidal sulfur, 1-2% of salicylic acid, 1-5% of plankton extract, 0.1-1.5% of allantoin acetyl methionine salt, 0.1-1% of hesperetin, 2-10% of modified montmorillonite, 2-5% of glycerol, 2-10% of mineral inorganic salt gel, 2-4% of a filtrate of a fermentation product of leuconostoc/radish root and the balance of water. The purifying liquid can slowly adjust the normal keratinization of the horny layer, recover the abnormal keratinization, stimulate sebaceous glands, control fungal infection and eliminate inflammation aiming at a first-step treatment scheme of seborrheic dermatitis, acarodermatitis and acne rosacea.
Description
Technical Field
The invention relates to the field of skin care products, and in particular relates to a purifying liquid for treating acarodermatitis.
Background
Demodex mites are permanent, small parasitic mites that colonize hair follicles and sebaceous glands of humans and mammals, take up intracellular nutrients and sebaceous gland secretions, thereby destroying normal cells. When the immunity of a human body is reduced, serious skin pathological changes can be caused, such as acarodermatitis, acarodentic acne and the like, and in addition, studies show that demodex has close relationship with seborrheic dermatitis, alopecia and the like appearing on the face of the human body.
Mite dermatitis and seborrheic dermatitis have in common a chronic inflammatory state, which is characterized by: redness and swelling of skin, excessive telangiectasia, acne-like, hypertrophic cutin, unbalanced flora, overproof malassezia, greasy skin, hyperplasia, dry and tight epidermis, and blocked pores.
Rosacea, also known as rosacea, is a skin disease characterized by redness of the nose, papules, pustules and telangiectasia, which are shaped like strawberries or well-done tomatoes. The skin lesion of the disease is usually rose red and similar to acne, so it is named rose acne. It is commonly seen in adults, and is often seen in people with more facial oil secretion. It is well in the center of the face, especially in the nose and sides, cheeks, glabella and chin, and is usually located at five points, namely the tip, glabella, cheeks, mandible and nasolabial sulcus. The cause of rosacea is also closely related to demodex.
The medicinal use of sulfur began during the period of Hippocrade and continued until now, especially in the treatment of acne. At least 5000 years ago, the ancient egyptian began to treat acne and eczema with sulfur-containing ointments; in the history of Chinese medicine, the history of sulfur in skin care dates back to yellow emperor, which is 2200 years at present. The disease mechanism of demodex is not clear, and the demodex is mainly used as a mite killing agent clinically, such as some sulfur-containing ointments, which have unreasonable formulas, poor pertinence and lack of skin nutrition protection components.
In addition, there are few products for treating the acne rosacea on the skin care product market, and without the step-by-step fine management treatment, one formula can cause the condition to be prolonged without symptomatic treatment or over treatment for all consumers suffering from the acne rosacea. The ophthalmic solution mainly uses azelaic acid and metronidazole gel with larger irritation or brimonidine tartrate eye drops for reducing the pressure of blood vessels to be matched with oral drugs, the time is longer, particularly the brimonidine tartrate eye drops have larger irritation, and the state of consumers is easily influenced by frequently taking anti-inflammatory drugs, such as vestibular imbalance, temporary solution treatment, permanent solution treatment and easy repetition.
Disclosure of Invention
Based on the technical background, the invention aims to provide the cleaning solution for treating the acarid dermatitis based on the synergy of the bioactive colloidal nano sulfur particles and the methionine salt. The first treatment scheme aiming at seborrheic dermatitis, acarodermatitis and acne rosacea can achieve the effects of slowly adjusting normal keratinization of a horny layer, recovering abnormal keratinization, stimulating sebaceous glands, controlling fungal infection and eliminating inflammation.
The invention is realized by the following technical scheme:
a cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in parts by weight: 1-15% of bioactive colloidal sulfur, 1-2% of salicylic acid, 1-5% of plankton extract, 0.1-1.5% of allantoin acetyl methionine salt, 0.1-1% of hesperetin, 2-10% of modified montmorillonite, 2-5% of glycerol, 2-10% of mineral inorganic salt gel, 2-4% of a filtrate of a fermentation product of leuconostoc/radish root and the balance of water.
Further, the dosage of the bioactive colloidal sulfur is preferably 3-12%, and more preferably 5-10%. The bioactive colloidal sulfur plays an important role in maintaining the health of connective tissue, as well as skin, bone, teeth, hair, and muscle. Methionine is involved in the synthesis of many methylated compounds, such as choline, creatine and epinephrine. The sulfur-containing amino acids enter a number of metabolic processes that directly or indirectly control the rate of tissue catabolism, sulfur, as a constituent of cysteine and methionine, is an essential component for protein synthesis in various organisms, replaces lost sulfhydryl groups, contributes to skin metabolism and stimulates epithelialization, preventing skin tissue breakdown. The efficacy of sulfur depends on its direct interaction with the skin. The smaller the particle size, the larger the range of action, and hence the more effective. The therapeutic effect of bioactive colloidal sulfur on skin prone to acne or excessive sebum secretion is attributed to its exfoliating activity. The use of high concentrations of sulfur allows the accumulation of certain amounts of hydrogen sulfide bonds to achieve an exfoliating effect, while the sulfur is converted to pentasulfuric acid on the skin by bacteria and keratinocytes to allow the fungus to be shed from the stratum corneum.
Further, the salicylic acid is dextrin-coated salicylic acid, wherein the content of the salicylic acid is 50%. The dextrin wraps the salicylic acid, and the dosage of the dextrin is preferably 1.2-1.8%. The plankton extract is a microalgae extract, and the dosage of the plankton extract is preferably 2-4%. The salicylic acid and the plankton extract which are cooperatively wrapped are the expression of key mediators for regulating and controlling sebum secretion and inflammation sources, and the effects of inhibiting excessive sebum secretion, relieving redness and inflammation are achieved by reducing the expression of an inflammatory factor C0X-2 participating in sebum secretion, so that pores are cleaned, the mitosis of the skin is reduced to a normal level, and the spreading of pimples and blackheads is prevented. The lipid solubility of salicylic acid can penetrate into the stratum corneum and deep pores and the hair follicle wall by fusing with lipid without causing irritation to the dermal tissue. The hair follicle-stimulating agent can permeate into the deep layer of a pore along a sebaceous gland which secretes grease, can dissolve the constitutional substances among cuticles, is beneficial to dissolving old and accumulated cuticles in the pore, corrects abnormal cell shedding, can help to clear blocked hair follicles, improves the situation of pore blockage, enables the cuticles to shed, can remove the cuticles accumulated thickly, and promotes metabolism.
Further, the allantoin acetylmethionine salt is preferably used in an amount of 0.1 to 1.2%, more preferably 0.1 to 1%. The allantoin acetyl methionine salt is a molecular compound obtained by combining allantoin and acetyl methionine in an equimolar ratio, shows a synergistic effect, and the synergistic effect of combining the allantoin and the acetyl methionine is shown to have high potential in permeating pores, gland pores and various skin pits, and has a beneficial effect on treating common acne and related dermatological diseases. In vitro studies showed that the allantoin acetylmethionine salt had 20 mm and 45 mm efficacy against staphylococcus aureus and propionibacterium acnes, respectively, as measured by the zone of inhibition around the paper discs impregnated with the product. In addition, allantoin acetyl methionate is also helpful for skin metabolism and stimulates epithelization; is helpful for preventing and stopping seborrheic dermatitis; and due to its keratolytic action, it helps in the dissolution of dry scale debris, restoring abnormal keratinization and stimulating sebaceous glands.
Further, the hesperetin is carboxymethylated hesperetin, and the dosage of the carboxymethylated hesperetin is preferably 0.1-0.8%, and more preferably 0.3-0.5%. Conventional hesperetin is difficult to dissolve in water, and the water solubility of hesperetin is increased after carboxymethylation, so that the effects of protecting and relieving skin pressure, improving the flexibility of blood vessels, repairing capillary walls and maintaining the integrity of the blood vessel walls are achieved. Is beneficial for improving epidermal cell tissue metabolism and substance exchange capacity, dredging microcirculation, preventing protein in blood vessel from dissociating out of blood vessel to cause swelling, resisting edema and exudation, inhibiting inflammatory factor release, reducing pimple and improving skin redness
Further, the amount of the modified montmorillonite is preferably 4 to 8%, more preferably 5 to 7%. The modified montmorillonite is refined inorganic clay salt prepared from natural minerals: the silicate sheets with 700 nm thickness and negatively charged surfaces are stacked by means of electrostatic interaction between layers, and the crystal structure of the silicate sheets has a unique one-dimensional layered structure and high-capacity cation exchange characteristics. The lamellar structure of the skin-care facial mask contains water, the water is gathered by micro scaly particles to form a cabin structure, montmorillonite with the average nano particle size is attached to the surface of the skin by 10 to 20 trillion particles, the protective facial mask is formed by the huge surface area, allergen is intercepted and isolated, the three-dimensional structure of the allergic protein is influenced by positive and negative charges, the allergen can be directionally decomposed by losing the bioactivity of the montmorillonite, and the natural inorganic clay salt has no harm to a human body.
Furthermore, the purifying liquid provided by the embodiment of the invention can also be applied to treatment of seborrheic dermatitis.
Furthermore, the purifying liquid provided by the embodiment of the invention can also be applied to treating acne rosacea.
The present invention is directed to a first step treatment regimen for seborrheic dermatitis, acarodermatitis, and rosacea. Colloidal nano octahedral sulfur with strong biological activity is utilized to synergize allantoin methionine salt and montmorillonite with a three-dimensional space structure to form a sulfur-hydrogen bond with skin stratum corneum cells, and when the sulfur-hydrogen bond is accumulated to a certain amount, the death stratum corneum and fungi on the skin can be stripped finally, so that the stratum corneum is normally cornified, and the renewal speed of the stratum corneum is accelerated; meanwhile, the device can help to pull out the hair follicle blocked by sebum secretion secreted by the sebaceous gland, and prevent the sebaceous gland duct and the hair follicle opening from being blocked. In addition, the anti-fungal-infection and anti-allergic agent can also resist fungal infection, condition and inactivate allergens secreted by mites, achieve the effect of inactivating the allergens by destroying the molecular structure of allergenic proteins, neutralize and condition the allergens, resist allergy, relieve itching, relieve redness and inflammation, inhibit sebum oxidation and increase the flexibility of capillary vessels. Has high potential of permeating pores, gland holes and various skin depressions, gently peels off cuticle, is beneficial to dissolving dry scales, and achieves the purposes of inhibiting bacteria and removing mites. Can regulate and control oil secretion, deeply clean pores and has the effect of controlling oil.
Compared with the prior art, the invention can be managed from a plurality of dimensions, and has the following beneficial effects:
1. has high potential of permeating pores, gland pores and various skin depressions, has the function of gently stripping stratum corneum, and is beneficial to dissolving dry scales;
2. has the oil control effect;
3. bacteriostasis, mite removal and allergen neutralization and conditioning;
4. anti-allergic, antipruritic, redness and inflammation relieving, sebum oxidation inhibiting, and capillary flexibility increasing effects.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
FIG. 1 is a comparison graph of a seborrheic dermatitis patient before and after use in one embodiment of the present invention;
FIG. 2 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
FIG. 3 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
FIG. 4 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
FIG. 5 is a comparison of a patient with rosacea before and after use in accordance with another embodiment of the invention;
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
[ first embodiment ] A method for manufacturing a semiconductor device
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 1% of bioactive colloidal sulfur, 1% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 1% of microalgae extract, 1.5% of allantoin acetyl methionine, 1% of carboxymethylated hesperetin, 10% of modified montmorillonite, 3% of glycerol, 7% of mineral inorganic salt gel, 2% of a filtrate of a fermentation product of leuconostoc/radish root and 72.5% of water.
[ second embodiment ]
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 5% of bioactive colloidal sulfur, 1% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 3% of microalgae extract, 0.1% of allantoin acetyl methionine, 0.1% of carboxymethylated hesperetin, 2% of modified montmorillonite, 5% of glycerol, 10% of mineral inorganic salt gel, 4% of a filtrate of a fermentation product of leuconostoc/radish root and 69.8% of water.
[ third embodiment ]
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 15% of bioactive colloidal sulfur, 2% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 5% of microalgae extract, 1% of allantoin acetyl methionine, 0.5% of carboxymethylated hesperetin, 5% of modified montmorillonite, 2% of glycerol, 2% of mineral inorganic salt gel, 2% of a filtrate of a fermentation product of leuconostoc/radish root and 65.5% of water.
[ fourth example ] A
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 12% of bioactive colloidal sulfur, 2% of dextrin-coated salicylic acid with the salicylic acid content of 50%, 2% of microalgae extract, 0.8% of allantoin acetylmethionine, 0.4% of carboxymethylated hesperetin, 9% of modified montmorillonite, 4% of glycerol, 6% of mineral inorganic salt gel, 2% of a filtrate of a Leuconostoc/radish root fermentation product and 61.8% of water.
[ fifth embodiment ]
A cleaning solution for treating acarid dermatitis based on bioactive colloidal nano sulfur particles and methionine salt, which comprises the following components in percentage by weight: 3% of bioactive colloidal sulfur, 1.2% of salicylic acid coated by dextrin with the salicylic acid content of 50%, 4% of microalgae extract, 1.2% of allantoin acetylmethionine, 0.9% of carboxymethylated hesperetin, 3% of modified montmorillonite, 4% of glycerol, 5% of mineral inorganic salt gel, 3% of a filtrate of a fermentation product of leuconostoc/radish root and 74.7% of water.
Seborrheic dermatitis is a chronic inflammation occurring on the basis of seborrhea, is damaged into bright red or yellowish red patches, is attached with greasy scales or crusts on the surface, and is often accompanied with pruritus of different degrees due to hypersecretion of skin glands, which is manifested by greasy scalp, greasy and shiny, more desquamation and is easy to occur in areas with developed sebum. Patient a is a typical seborrheic dermatitis patient with red and swollen skin, excessive telangiectasia, acne, hypertrophic cutin, unbalanced flora, overproof malassezia, greasy and hyperplastic skin, dry and tight epidermis, and also with skin pruritus according to the patient's dictation. After cleaning the face in the morning and evening, the cleansing liquid prepared in the first embodiment is applied to the affected part, the skin is obviously improved after one week, the red swelling of the skin is subsided, the epidermis is not dry any more, no white scale is seen, and 90% of acnes are treated. FIG. 1 is a graph comparing the effect of patient A before and after treatment with an embodiment of the invention.
Rosacea, also known as rosacea, is a skin disease characterized by redness of the nose, papules, pustules and telangiectasia, which are shaped like strawberries or well-done tomatoes. The skin lesion of the disease is usually rose red and similar to acne, so it is named rose acne. It is well in the center of the face, especially in the nose and sides, cheeks, glabella and chin, and is usually located at five points, namely the tip, glabella, cheeks, mandible and nasolabial sulcus.
Rosacea is clinically generally characterized by three stages, the first stage of erythema: it is manifested as erythema in the middle of the face, especially in the nose, cheeks and mandible, especially after an irritant diet, external temperature changes and mental excitation. Erythema is initially transient and develops into persistent telangiectasias over time, often most pronounced at the tip and lateral alars of the nose. Stage two papulopustular: acne-like papules or pustules appear on the basis of erythema, and the capillaries dilate more obviously and are criss-cross. Third stage nasal wart: in the long term, the nasal connective tissue is hyperplastic, and the sebaceous glands are abnormally enlarged, which results in the swelling of the nasal tip and the formation of nodular bulges of different sizes, called as the nose tag. The surface is uneven, the sebaceous gland orifice is obviously enlarged, white viscous sebum secretion overflows after being squeezed, and the capillary vessel is obviously expanded.
Patient B is a typical erythroid patient, in the early stages of rosacea, exhibiting predominantly flushing facial features. After cleaning the face in the morning and evening, the cleansing liquid prepared in the second example is applied to the affected part, and the affected part is obviously improved after one week, the flushing of the face is eliminated, the secretion of grease is reduced, and the skin is clean and fresh. FIG. 2 is a graph comparing the effect of patient B before and after treatment with an embodiment of the invention.
Patient C is a typical erythema stage patient with telangiectasia and, on erythema basis, a small number of acneiform papules. After cleaning the face in the morning and evening, the cleansing liquid prepared in the third example is applied to the affected part, the affected part is obviously improved after one week, the flushing on the face is relieved, more than 90% of papules are cured, and the capillary vessels are restored to the normal level. Figure 3 is a graph comparing the effect of patient C before and after treatment with an embodiment of the invention.
Patient D was a patient with rosacea at the second stage of papulopustular stage, with marked telangiectasia, criss-cross pattern, large areas of papules and pustules on the skin surface, redness of the face with itching, and clinically severe rosacea. The cleansing liquid prepared in the fourth example was applied to the affected part after cleansing in the morning and evening, and the effect is shown in fig. 4. It can be seen from the figure that the change is obvious every three days, the change is completely improved after two weeks, the papules and pustules on the face are completely cured, pores are fine and smooth, and no scar is seen.
Patient E was the most severe patient with rosacea, in the nose wart stage, with hyperplasia of nasal connective tissue and abnormal enlargement of sebaceous glands, resulting in swollen nasal tip, formation of nodular bumps of varying sizes, uneven nasal surface, significant enlargement of sebaceous glands, extrusion of white viscous sebaceous secretions, and significant dilation of capillaries. In addition, symptoms in the first two stages, flushing of the face, small papules on the cheeks and seborrheic dermatitis were observed. The cleansing liquid prepared in the fourth example was applied to the affected part after cleansing the face in the morning and evening, and two weeks later, the effect was clearly improved. The swelling of the nose tip subsides, the surface is smooth, the capillary vessels shrink to the normal level, the sebaceous glands shrink obviously, the flushing subsides, and the pimple is cured. FIG. 5 is a graph comparing the effect of patient E before and after treatment with an embodiment of the invention.
Therefore, the invention can perform targeted management on the skin from multiple dimensions, has high potential of penetrating into pores, gland holes and various skin depressions, has the function of gently stripping the stratum corneum and is beneficial to dissolving dry scales; has the oil control effect; can inhibit bacteria, remove mites, neutralize and condition allergens; it also has anti-allergic, antipruritic, redness relieving, inflammation relieving, sebum oxidation inhibiting, and capillary flexibility improving effects.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (9)
1. The cleaning solution for treating the mite dermatitis based on the synergy of the bioactive colloidal nano sulfur particles and the methionine salt is characterized by comprising the following components in parts by weight: 1-15% of bioactive colloidal sulfur, 1-2% of salicylic acid, 1-5% of plankton extract, 0.1-1.5% of allantoin acetyl methionine salt, 0.1-1% of hesperetin, 2-10% of modified montmorillonite, 2-5% of glycerol, 2-10% of mineral inorganic salt gel, 2-4% of a filtrate of a fermentation product of leuconostoc/radish root and the balance of water.
2. The purification solution of claim 1, wherein the salicylic acid is a dextrin-coated salicylic acid.
3. The purification solution of claim 2, wherein the dextrin encapsulates salicylic acid, the salicylic acid content being 50%.
4. The purification solution of claim 1, wherein the plankton extract is a microalgae extract.
5. The purification liquid as claimed in claim 1, wherein the allantoin acetylmethionine salt is a molecular complex obtained by combining allantoin and acetylmethionine in an equimolar ratio.
6. The purification solution of claim 1, wherein the hesperetin is carboxymethylated hesperetin.
7. The purification solution of claim 1, wherein the modified montmorillonite is a refined inorganic clay salt made from natural minerals.
8. Use of a purification solution according to any one of claims 1 to 7 for the treatment of seborrheic dermatitis.
9. Use of a purification solution according to any one of claims 1 to 7 for the treatment of rosacea.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011006481.9A CN111920757B (en) | 2020-09-23 | 2020-09-23 | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011006481.9A CN111920757B (en) | 2020-09-23 | 2020-09-23 | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111920757A true CN111920757A (en) | 2020-11-13 |
CN111920757B CN111920757B (en) | 2021-05-11 |
Family
ID=73334043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011006481.9A Active CN111920757B (en) | 2020-09-23 | 2020-09-23 | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111920757B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113425666A (en) * | 2021-07-06 | 2021-09-24 | 科丝美诗(中国)化妆品有限公司 | Composition for removing acne and repairing skin barrier as well as preparation method and application thereof |
CN115715754A (en) * | 2022-11-29 | 2023-02-28 | 昆明医科大学 | Gel with acne removing and repairing effects and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101317862A (en) * | 2005-11-18 | 2008-12-10 | 赵中州 | Medicament for treating acarodermatitis of human face and preparation method thereof |
WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
CN101460060A (en) * | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | Composition and method for topical treatment of tar-responsive dermatological disorders |
JP2014114290A (en) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | Cosmetic and skin external preparation |
CN107684530A (en) * | 2017-08-25 | 2018-02-13 | 深圳市雪绒蓝天化妆品贸易有限公司 | Acne-removing composition and preparation method thereof |
CN109528756A (en) * | 2017-09-21 | 2019-03-29 | 扬中牧乐药业有限公司 | A kind of sulfur ointment for treating mink mange and scab |
-
2020
- 2020-09-23 CN CN202011006481.9A patent/CN111920757B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101317862A (en) * | 2005-11-18 | 2008-12-10 | 赵中州 | Medicament for treating acarodermatitis of human face and preparation method thereof |
CN101460060A (en) * | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | Composition and method for topical treatment of tar-responsive dermatological disorders |
WO2009046116A1 (en) * | 2007-10-01 | 2009-04-09 | Dennis Gross | Skin care products containing multiple enhancers |
JP2014114290A (en) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | Cosmetic and skin external preparation |
CN107684530A (en) * | 2017-08-25 | 2018-02-13 | 深圳市雪绒蓝天化妆品贸易有限公司 | Acne-removing composition and preparation method thereof |
CN109528756A (en) * | 2017-09-21 | 2019-03-29 | 扬中牧乐药业有限公司 | A kind of sulfur ointment for treating mink mange and scab |
Non-Patent Citations (2)
Title |
---|
G: "丹姿⽔密码美容液", 《HTTP://WWW.COSDNA.COM/CHS/COSMETIC_342B37542.HTML》 * |
无: "ETUDE (爱丽) House Zero Sebum Clearing Powder Toner", 《HTTP://WWW.COSDNA.COM/CHS/COSMETIC_A994277568.HTML》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113425666A (en) * | 2021-07-06 | 2021-09-24 | 科丝美诗(中国)化妆品有限公司 | Composition for removing acne and repairing skin barrier as well as preparation method and application thereof |
CN115715754A (en) * | 2022-11-29 | 2023-02-28 | 昆明医科大学 | Gel with acne removing and repairing effects and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111920757B (en) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2320362C2 (en) | Proanthocyanidin-containing topical pharmaceutical compositions for treatment of dermatitis | |
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
US9962402B2 (en) | Healing composition for topical application | |
CN111920757B (en) | Purification liquid for treating acarid dermatitis based on synergy of bioactive colloidal sulfur nanoparticles and methionine salt | |
US7655255B2 (en) | Topical composition for transdermal administration | |
US20190240088A1 (en) | Methods and compositions for treatment of skin conditions | |
US9107818B2 (en) | Method of debriding tissue | |
US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
US10071052B2 (en) | Method for the prevention and treatment of acne | |
US11576926B2 (en) | Composition for use in the prevention and/or treatment of epistaxis | |
EP3348307B1 (en) | Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis | |
US20240226085A1 (en) | Kynrenine and derivatives thereof for treating atrophic scarring | |
EP4085913A1 (en) | Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea | |
RU2325900C2 (en) | Skin composition of external application | |
CN112791093A (en) | Transdermal drug delivery composition for treating acne and preparation method thereof | |
TWI325324B (en) | ||
KR20190132197A (en) | Cosmetic composition for use in the treatment and prevention of acne-prone skin | |
KR20060134261A (en) | Pharmaceutical compositions for allergic dermattitis containing gold-nanosolution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |